{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:46:49Z","timestamp":1769633209219,"version":"3.49.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/inf.0000000000000240","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T12:05:29Z","timestamp":1387454729000},"page":"703-709","source":"Crossref","is-referenced-by-count":78,"title":["Motavizumab Treatment of Infants Hospitalized With Respiratory Syncytial Virus Infection Does Not Decrease Viral Load or Severity of Illness"],"prefix":"10.1097","volume":"33","author":[{"given":"Octavio","family":"Ramilo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Lagos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"S\u00e1ez-Llorens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn","family":"Suzich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Kathy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn M.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve A.","family":"Losonsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Pamela","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210202","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid.","volume":"137","author":"Boyce","year":"2000","journal-title":"J Pediatr"},{"key":"R2-6-20210202","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/INF.0b013e31822e68e6","article-title":"Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.","volume":"31","author":"Stockman","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R3-6-20210202","doi-asserted-by":"crossref","first-page":"e1072","DOI":"10.1542\/peds.2008-3074","article-title":"Relative impact of influenza and respiratory syncytial virus in young children.","volume":"124","author":"Bourgeois","year":"2009","journal-title":"Pediatrics"},{"key":"R4-6-20210202","first-page":"221","article-title":"Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis.","volume":"1","author":"Bont","year":"2000","journal-title":"Paediatr Respir Rev"},{"key":"R6-6-20210202","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1399-3038.2005.00298.x","article-title":"Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study.","volume":"16","author":"Henderson","year":"2005","journal-title":"Pediatr Allergy Immunol"},{"key":"R9-6-20210202","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1542\/peds.100.6.937","article-title":"Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children.","volume":"100","author":"Rodriguez","year":"1997","journal-title":"Pediatrics"},{"key":"R10-6-20210202","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.inf.0000133165.85909.08","article-title":"MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.","volume":"23","author":"Saez-Llorens","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R11-6-20210202","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/314523","article-title":"Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.","volume":"178","author":"Malley","year":"1998","journal-title":"J Infect Dis"},{"key":"R12-6-20210202","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/INF.0b013e3181a165e4","article-title":"Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.","volume":"28","author":"Lagos","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R13-6-20210202","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1128\/JCM.41.1.149-154.2003","article-title":"Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR.","volume":"41","author":"Hu","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R14-6-20210202","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1542\/peds.2008-1036","article-title":"Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.","volume":"125","author":"Carbonell-Estrany","year":"2010","journal-title":"Pediatrics"},{"key":"R15-6-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0022-3476(97)70342-1","article-title":"Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial.","volume":"130","author":"Klassen","year":"1997","journal-title":"J Pediatr"},{"key":"R16-6-20210202","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1203\/PDR.0b013e318220a553","article-title":"Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.","volume":"70","author":"Feltes","year":"2011","journal-title":"Pediatr Res"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:02:45Z","timestamp":1620954165000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201407000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000240","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}